Imaging and therapeutic targeting of prostate and bladder...

Details Imaging and therapeutic targeting of prostate and bladder... Imaging and therapeutic targeting of prostate and bladder...

2011-04-05

2011-04-05

Kosar, Andrew D (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

Reexamination Certificate

active

07919579

ABSTRACT:
The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

REFERENCES:
patent: 6610657 (2003-08-01), Goueli
patent: WO 0183554 (2001-11-01), None
Borley et al., “Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high-risk” prostate cancer compared to MRI or CT,”Scand. J. Urol. Nephrol., 37:382-386, 2003.
Boswell et al., “Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes,”J. Med. Chem., 47:1465-1474, 2004.
Carter et al., “Nonpalpable prostate cancer: detection with MR imaging,”Radiology, 178:523-525, 1991.
Derossi et al., “Trojan peptides: the penetratin system for intracellular delivery,”Trends in Cell Biol., 8:84-87, 1998.
Deshayes et al., “Cell-penetrating peptides: tools for intracellular delivery of therapeutics,”Cell Mol. Life Sci., 62:1839-1849, 2005.
Drin et al., “Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors,”AAPS Pharm. Sci., 4:26, 2002.
El-Andaloussi et al., “Cell-penetrating peptides: mechanisms and applications,”Curr. Pharm. Des., 11:3597-3611, 2005.
Ferrari, “Cancer nanotechnology: opportunities and challenges,”Nat. Rev. Cancer, 5:161-171, 2005.
Fischer et al., “A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides,”J. Biol. Chem., 279:12625-12635, 2004.
Futaki et al., “Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery,”J. Biol. Chem., 276:5836-5840, 2001.
Futaki et al., “RNase S complex bearing arginine-rich peptide and anti-HIV activity,”J. Mol. Recognit., 18:169-174, 2005.
Gioeli et al., “Activation of mitogen-activated protein kinase associated with prostate cancer progression,”Cancer Res., 59:279-284, 1999.
Gupta and Gupta, “Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications,”Biomaterials, 26:3995-4021, 2005.
Hersh et al., “Newer imaging modalities to assess tumor in the prostate,”Cancer Control, 11:353-357, 2004.
Jager et al., “Prostate cancer staging: should MR imaging be used?—A decision analytic approach,”Radiology, 215:445-451, 2000.
Jana and Blaufox, “Nuclear medicine studies of the prostate, testes, and bladder,”Semin. Nucl. Med., 36:51-72, 2006.
Mayer, “SH3 domains: complexity in moderation,”J. Cell Sci., 114:1253-1263, 2001.
Noguchi et al., “A new cell-permeable peptide allows successful allogeneic islet transplantation in mice,”Nat. Med., 10:305-309, 2004.
Pooga et al., “Cell penetration by transportan,”FASEB J., 12:67-77, 1998.
Price et al., “Activation of extracellular signal-regulated kinase in human prostate cancer,”J. Urol., 162:1537-1542, 1999.
Quinn et al., “MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens,”Radiology, 190:323-327, 1994.
Saar et al., “Cell-penetrating peptides: a comparative membrane toxicity study,”Anal. Biochem., 345:55-65, 2005.
Schöder and Larson, “Positron emission tomography for prostate, bladder, and renal cancer,”Semin. Nucl. Med., 34:274-292, 2004.
Schwarze et al., “In vivo protein transduction: delivery of a biologically active protein into the mouse,”Science, 285:1569-1572, 1999.
Sumers, “Staging prostate cancer with MR imaging,”Radiology, 187:875, 1993.
Sun et al., “In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands,”J. Biol. Inorg. Chem., 8:217-225, 2003.
Sun et al., “In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands,”Nucl. Med. Biol., 31:1051-1059, 2004.
Sun et al., “Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands,”J. Med. Chem., 45:469-477, 2002.
Torchilin, “Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate,”Adv. Drug Deliv. Rev., 57:95-109, 2005.
Turner et al., “Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells,”Nucleic Acids Res., 33:6837-6849, 2005.
Vidal et al., “SH2 and SH3 domains as targets for anti-proliferative agents,”Crit. Rev. Oncol. Hematol., 40:175-186, 2001.
Vivès et al., “A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus,”J. Biol. Chem., 272:16010-16017, 1997.
Wadia and Dowdy, “Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer,”Adv. Drug Deliv. Rev., 57:579-596, 2005.
Wender et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters,”Proc. Natl. Acad. Sci. USA, 97:13003-13008, 2000.
Xie et al., “Protein transduction domain of membrane penetrating peptide can efficiently deliver DNA and protein into mouse liver for gene therapy,”Hepatobiliary Pancreat. Dis. Int., 4:90-93, 2005.
Zhou and Hsieh, “The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2,”J. Biol. Chem., 276:27793-27798, 2001.
Zhou et al., “Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer,”J. Biol. Chem., 278:6936-6941, 2003.
Zhou et al., “Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle,”Cancer Res., 66:8954-8958, 2006.
Zhou et al., “Signal transduction targets in androgen-independent prostate cancer,”Cancer&Met. Rev., 20:351-362, 2001.
Zhou et al., “Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor,”Cancer Res., 65:6089-6096, 2005.
Ziegler et al., “The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence,”Biochemistry, 44:138-148, 2005.

Affiliated with

Also associated with

Rating

Imaging and therapeutic targeting of prostate and bladder... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imaging and therapeutic targeting of prostate and bladder..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imaging and therapeutic targeting of prostate and bladder... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2690189